Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours.

Auteurs : Awada A, Hendlisz A, Christensen O, Lathia CD, Bartholomeus S, Lebrun F, de Valeriola D, Brendel E, Radtke M, Delaunoit T, Piccart-Gebhart M, Gil T
Année : 2012
Journal : Eur. J. Cancer
Volume : 48(4)
Pages : 465-74

A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer.

Auteurs : Schuler M, Awada A, Harter P, Canon JL, Possinger K, Schmidt M, De Grève J, Neven P, Dirix L, Jonat W, Beckmann MW, Schütte J, Fasching PA, Gottschalk N, Besse-Hammer T, Fleischer F, Wind S, Uttenreuther-Fischer M, Piccart-Gebhart M, Harbeck N
Année : 2012
Journal : Breast Cancer Res. Treat.
Volume : 134(3)
Pages : 1149-59

Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions.

Auteurs : Pradeep CR, Zeisel A, Köstler WJ, Lauriola M, Jacob-Hirsch J, Haibe-Kains B, Amariglio N, Ben-Chetrit N, Emde A, Solomonov I, Neufeld G, Piccart-Gebhart M, Sagi I, Sotiriou C, Rechavi G, Domany E, Desmedt C, Yarden Y
Année : 2012
Journal : Oncogene
Volume : 31(31)
Pages : 3569-83

Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries.

Auteurs : Saini KS, Taylor C, Ramirez AJ, Palmieri C, Gunnarsson U, Schmoll HJ, Dolci SM, Ghenne C, Metzger-Filho O, Skrzypski M, Paesmans M, Ameye L, de Azambuja E, Piccart-Gebhart M
Année : 2012
Journal : Ann Oncol
Volume : 23(4)
Pages : 853-859

Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy.

Auteurs : Hendlisz A, Golfinopoulos V, Garcia C, Covas A, Emonts P, Ameye L, Paesmans M, Deleporte A, Machiels G, Toussaint E, Vanderlinden B, Awada A, Piccart-Gebhart M, Flamen P
Année : 2012
Journal : Ann Oncol
Volume : 23(7)
Pages : 1687-93

The biological features and prognosis of breast cancer diagnosed during pregnancy: A case-control study.

Auteurs : Azim HA, Botteri E, Renne G, Dell orto P, Rotmensz N, Gentilini O, Sangalli C, Pruneri G, Di Nubila B, Locatelli M, Sotiriou C, Piccart-Gebhart M, Goldhirsch A, Viale G, Peccatori F
Année : 2012
Journal : Acta oncol (Stockholm)
Volume : 51(5)
Pages : 653-61

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.

Auteurs : Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, Cutter D, Darby S, Mcgale P, Taylor C, Wang YC, Bergh J, Di Leo A, Albain K, Swain S, Piccart-Gebhart M, Pritchard K
Année : 2012
Journal : Lancet
Volume : 379(9814)
Pages : 432-44

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

Auteurs : Baselga J, Campone M, Piccart-Gebhart M, Burris HA, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN
Année : 2012
Journal : N Engl J Med
Volume : 366(6)
Pages : 520-9

Triple-negative breast cancer in focus: from biology to novel therapeutics. Editorial.

Auteurs : Piccart-Gebhart M
Année : 2012
Journal : Ann Oncol
Volume : 23 Suppl 6
Pages : vi5-vi6

A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints.

Auteurs : Fumagalli D, Bedard PL, Nahleh Z, Michiels S, Sotiriou C, Loi S, Sparano JA, Ellis M, Hylton N, Zujewski JA, Hudis C, Esserman L, Piccart-Gebhart M
Année : 2012
Journal : Lancet Oncol
Volume : 13(6)
Pages : e240-8

Liquid biopsy to test new treatment strategies in breast cancer: are we there yet?

Auteurs : Ignatiadis M, Piccart-Gebhart M
Année : 2012
Journal : Ann Oncol
Volume : 23(7)
Pages : 1653-5

Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial.

Auteurs : Fernández-Cuesta L, Oakman C, Falagan-Lotsch P, Smoth KS, Quinaux E, Buyse M, Dolci MS, de Azambuja E, Hainaut P, + collaborators (among others :, Larsimont D, Piccart-Gebhart M, Olivier M
Année : 2012
Journal : Breast Cancer Res
Volume : 14(3)
Pages : R70

Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling.

Auteurs : Azim HA, Michiels S, Bedard PL, Singhal SK, Criscitiello C, Ignatiadis M, Haibe-Kains B, Piccart-Gebhart M, Sotiriou C, Loi S
Année : 2012
Journal : Clin Cancer Res
Volume : 18(5)
Pages : 1341-51

Characterization and clinical evaluation of CD10+ stroma cells in the breast cancer microenvironment.

Auteurs : Desmedt C, Majjaj S, Kheddoumi N, Singhal SK, Haibe-Kains B, El Ouriaghli F, Chaboteaux C, Michiels S, Lallemand F, Journe F, Duvillier H, Loi S, Quackenbush J, Dekoninck S, Blanpain C, Lagneaux L, Houhou N, Delorenzi M, Larsimont D, Piccart-Gebhart M, Sotiriou C
Année : 2012
Journal : Clin Cancer Res
Volume : 18(4)
Pages : 1004-14

Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis.

Auteurs : Ignatiadis M, Singhal SK, Desmedt C, Haibe-Kains B, Criscitiello C, Andre F, Loi S, Piccart-Gebhart M, Michiels S, Sotiriou C
Année : 2012
Journal : J. Clin. Oncol.
Volume : 30(16)
Pages : 1996-2004

Molecular biology in breast cancer: Should molecular classifiers be assessed by conventional tools or by gene expression arrays?

Auteurs : Fumagalli D, Andre F, Piccart-Gebhart M, Sotiriou C, Desmedt C
Année : 2012
Journal : Crit Rev Oncol Hematol
Volume : 84 supl 1
Pages : e58-69

Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence.

Auteurs : Rossari JR, Metzger-Filho O, Paesmans M, Saini KS, Gennari A, de Azambuja E, Piccart-Gebhart M
Année : 2012
Journal : J Oncol
Volume : 2012
Pages : 417673

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

Auteurs : Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horváth Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber Rd, Piccart-Gebhart M
Année : 2012
Journal : Lancet
Volume : 379(9816)
Pages : 633-40

Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines?

Auteurs : Burstein HJ, Piccart-Gebhart M, Perez EA, Hortobagyi GN, Wolmark N, Albain KS, Norton L, Winer EP, Hudis CA
Année : 2012
Journal : J. Clin. Oncol.
Volume : 30(18)
Pages : 2179-82

Examining the relationships among health-related quality-of-life indicators in cancer patients participating in clinical trials: a pooled study of baseline EORTC QLQ-C30 data.

Auteurs : Martinelli F, Quinten C, Maringwa JT, Coens C, Vercauteren J, Cleeland CS, Flechtner H, Gotay C, Greimel E, King M, Mendoza T, Osoba D, Reeve BB, Ringash J, Koch JS, Shi Q, Taphoorn MJ, Weis J, Bottomley A, + collaborators (among others :, Piccart-Gebhart M
Année : 2011
Journal : Expert Rev Pharmacoecon Outcomes Res
Volume : 11(5)
Pages : 587-99